Physician profile
Patrick O Godwin
NPI 1801986351
$108,755.75
in general payments reported to CMS, 2019-2025
6 companies · $7,940 in 2025
The $7,940 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $14K · 2021: $3,106 · 2022: $12K · 2023: $29K · 2024: $25K · 2025: $7,940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Consulting Fee: $17K · Travel and Lodging: $9,295 · Food and Beverage: $3,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,975.00 |
| Consulting Fee | $16,835.00 |
| Travel and Lodging | $9,294.65 |
| Food and Beverage | $3,759.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $75,124.08 | 2021-2025 | Veklury |
| Janssen Pharmaceuticals, INC | $33,153.84 | 2019-2021 | |
| Abbvie INC. | $271.87 | 2021-2022 | |
| Allergan, INC. | $110.48 | 2020 | |
| Pfizer INC. | $81.50 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.98 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Godwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.